Abstract
The initial process development of the novel β-lactamase inhibitor WCK 6395 is described. All key intermediates were readily isolated by either crystallization or precipitation to eliminate related impurities. Seven possible process-related impurities were hypothesized, and initial control strategies were implemented. Additionally, process parameters were identified and improved to decrease or circumvent these impurities. The parameters of each step were optimized through prior knowledge and experimentation to improve yield and desired quality of WCK 6395 to support toxicological studies. The improved process effectively reduced the use of hazardous reagents, was robust on the kilogram scale, demonstrated at the pilot scale, and subsequently served as the basis for commercial route development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
